Stockscreener 앱 받기
9.08
5.61%
-0.54
시간 외 거래:
9.08
Anteris Technologies Global Corp 주식(AVR)의 최신 뉴스
Anteris (NASDAQ: AVR) signs $250M at-the-market sales agreement with TD Cowen - Stock Titan
Anteris Technologies Global Corp plans to issue up to $250 million in common stock through TD Cowen as the underwriter. - Bitget
Anteris Technologies Global Launches $250 Million ATM Offering Under Sales Agreement With TD Cowen - TradingView
Anteris (NASDAQ: AVR) launches $250M at-the-market share program - Stock Titan
Anteris Technologies (NASDAQ: AVR) establishes $250M ATM with TD Cowen - Stock Titan
ChartWatch ASX Scans: Brazilian Rare Earths, Echoiq, Weebit Nano. Anteris Technologies, Global X Semiconductor ETF - Market Index
Anteris Technologies Global : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Director Susan Knight reports initial insider status at Anteris (NASDAQ: AVR) - Stock Titan
Number of shareholders of Anteris Technologies Global Corp. – NASDAQ:AVR - TradingView
Nantahala holds 6,143,154 shares of Anteris (AVR) as of 03/31/2026 - Stock Titan
AVR Maintained by Barclays -- Price Target Raised to $18.00 - GuruFocus
Anteris Technologies Global Corp. (AVR) Gets a Buy from TD Cowen - The Globe and Mail
Anteris Announces Results for the First Quarter of 2026 - Sahm
Anteris Technologies Adds Experienced Financial Leaders to Board - The Globe and Mail
TradingKey - TradingKey
Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation - Yahoo Finance
How Should Investors Value Anteris Technologies Global Corp (AVR - GuruFocus
Anteris Technologies appoints two directors to board - Investing.com
Anteris Technologies appoints two directors to board By Investing.com - Investing.com South Africa
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors - The Manila Times
Two experienced directors join Anteris as it advances DurAVR heart valve - Stock Titan
Anteris Technologies Reports Q1 2026 Results: $320M Raised and Key Milestones in PARADIGM Trial for DurAVR THV System - Minichart
Anteris Technologies Global Corp. Files Form 8-K for Nasdaq Listing and Company Details (May 12, 2026) - Minichart
Anteris Technologies Global adds Susan Knight and Stephen Denaro to board - Investing.com
Anteris Technologies Global Starts US PARADIGM Trial Enrolment - smallcaps.com.au
Anteris Technologies Posts Narrower Q1 Loss, Lower Net Sales - Moomoo
Why Market Is Bullish on Anteris Technologies (ASX:AVR) Today - Kalkine
Anteris adds seasoned finance leaders to board as structural heart push continues - TipRanks
Anteris Technologies Q1 2026 Results: DurAVR™ THV Trial Progresses, Cash Balance at $64.9 Million - geneonline.com
Anteris Technologies Global Corp reports results for the quarter ended March 31Earnings Summary - TradingView
AVR: DurAVRⓇ THV system adoption grows, with Q1 2026 payments to related parties at US$2.3M - TradingView
Anteris Technologies Global Corp. 1Q 2026: Revenue $494K, EPS ($0.28) — 10-Q Summary - TradingView
Anteris Technologies (Nasdaq: AVR) posts Q1 2026 loss, raises $320M for DurAVR trial - Stock Titan
Anteris Technologies Global Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Anteris Technologies Global Corp at Barclays Global Healthcare Conference Transcript - GuruFocus
Anteris Technologies Global Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances | ASX:AVR, NASDAQ:AVR - Proactive financial news
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances - Yahoo Finance
Anteris Technologies Enrolls First US Patients in PARADIGM Trial; Shares Up 6% - marketscreener.com
First U.S. patients enrolled in Anteris heart valve trial By Investing.com - Investing.com South Africa
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial - The Manila Times
Anteris Technologies begins U.S. enrollment in heart valve trial - StreetInsider
First U.S. patients enter Anteris heart valve trial for stenosis - Stock Titan
Anteris Sees CDI Decline as Investors Shift to Nasdaq-Listed Common Stock - TipRanks
Sio Capital (AVR) reports 5.38M shares, 5.54% stake as of Mar 31, 2026 - Stock Titan
AVR Stock Price, Quote & Chart | ANTERIS TECHNOLOGIES GLOBAL (NASDAQ:AVR) - ChartMill
Anteris Ends v2vmedtech Development Agreement, Limits Exposure - The Globe and Mail
Anteris Technologies Global Corp. (NASDAQ: AVR) registers 9.10M shares; discontinues v2v contributions - Stock Titan
Anteris Technologies Exits v2vmedtech Development Agreement, to Pay $400,000 Break Fee, Shares Up 3% - marketscreener.com
Anteris Technologies Exits V2vmedtech Development Agreement, to Pay $400,000 Break Fee, Shares Up 3% - 富途牛牛
Anteris Walks Away From v2vmedtech Funding Deal With Limited Financial Impact - TipRanks
Anteris Technologies ends development agreement with v2vmedtech, pays $400,000 fee By Investing.com - Investing.com South Africa
Anteris Technologies ends development agreement with v2vmedtech, pays $400,000 fee - Investing.com
1.04%
0.04%
자본화:
|
볼륨(24시간):